FormFactor Inc. FormFactor Inc. Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? FormFactor Inc. FormFactor Inc. Common Stock trades at $117.41 (market cap $10.01B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: FormFactor Inc. FormFactor Inc. Common Stock is far larger — about 5.6× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, FormFactor Inc. FormFactor Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold FormFactor Inc. FormFactor Inc. Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| FORM | VIR | |
|---|---|---|
Market Cap | $10.01B | $1.80B |
Volume | 1,445,909 | 1,782,836 |
Sector | Technology | Health |
52-Week High | $159.93 | $11.78 |
52-Week Low | $41.29 | $5.12 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $9.69B | $1.36B |
Signals from Pluang's Aura AI — not financial advice
FormFactor (FORM) trades at $128.09, down 1.68% on the day, amid a bullish technical setup with key support at $127. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 28. Revenue and net income are projected to grow significantly in 2026, though valuation ratios remain elevated.
The outlook is positive, driven by strong AI-driven semiconductor demand and strategic collaborations, but high P/E and P/S ratios pose valuation risks. Analyst consensus is bullish with a $154.71 price target, though insider selling and negative cash flow in 2025 warrant caution.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FormFactor, Inc. provides semiconductor test and measurement technologies used across the integrated circuit lifecycle, manufacturing probe cards and analytical probes through its Probe Cards segment and probe stations, thermal systems, and cryogenic systems through its Systems segment.
Read more on FORM →Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →